Coeliac disease—a future for peptide therapy?
- 1 July 2000
- journal article
- Published by Elsevier in The Lancet
- Vol. 356 (9226), 270-271
- https://doi.org/10.1016/s0140-6736(00)02499-5
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitopeNature Medicine, 2000
- The Intestinal T Cell Response to α-Gliadin in Adult Celiac Disease Is Focused on a Single Deamidated Glutamine Targeted by Tissue TransglutaminaseThe Journal of Experimental Medicine, 2000
- T cells orchestrate intestinal mucosal shape and integrityImmunology Today, 1999
- Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma.Gut, 1995
- The Three-Dimensional Structure of Peptide-MHC ComplexesAnnual Review of Immunology, 1995
- In Vitro Toxicity of Gluten Peptides in Coeliac Disease Assessed by Organ CultureScandinavian Journal of Gastroenterology, 1995
- T cells recognize a peptide derived from α-gliadin presented by the celiac disease-associated HLA-DQ (α1∗0501, β1∗0201) heterodimerHuman Immunology, 1994
- Wheat peptide challenge in coeliac diseaseThe Lancet, 1994
- HLA susceptibility genes in celiac disease: Genetic mapping and role in pathogenesisGastroenterology, 1993
- In vivo Toxicity of a Synthetic Dodecapeptide from a Gliadin in Patients with Coeliac DiseaseScandinavian Journal of Gastroenterology, 1991